Molecular Cancer Therapeutics

Table of Contents

AACR American Association for Cancer Research

February 2019 • Volume 18 • Number 2

Highlights of This Issue 233

SMALL MOLECULE THERAPEUTICS

LARGE MOLECULE THERAPEUTICS

CANCER BIOLOGY AND TRANSLATIONAL STUDIES

Table of Contents

AC icon indicates AuthorChoice
For more information please visit www.aacrjournals.org

Table of Contents

ABOUT THE COVER

Abemaciclib, a cyclin-dependent kinase 4 and 6 dual inhibitor, was recently approved for the treatment of breast cancer. However, diarrhea is a common adverse event observed in patients treated with abemaciclib. Therefore, Thibault and colleagues sought to determine if toxicity was due to CDK4/6 inhibition or instead due to secondary pharmacological targets. Shown is an image of *in situ* hybridization (ISH) of rats administered 120 mg/kg abemaciclib using brown reagent with hematoxylin (blue) background. The representative section demonstrated an increased number of crypt cells staining for Smoc2, consistent and proportional to the elongation of the crypts in rats administered abemaciclib. For details, see article on page 257.



Molecular Cancer Therapeutics

18 (2)

Mol Cancer Ther 2019;18:233-493.